Research Use Only
Semaglutide vs Tirzepatide
Neutral RUO comparison of Semaglutide and Tirzepatide using public protocol-library fields: vial size, research class, mechanism, evidence level and references.
Public fields onlyReferences included
This page compares only public, research-context fields from the AllPeptides protocol library. It is not a ranking, recommendation, safety comparison or human-use guide.
Public research comparison fields
| Field | Semaglutide | Tirzepatide |
|---|---|---|
| Name | Semaglutide | Tirzepatide |
| Representative vial size | 2.5mg | 5mg |
| Research class | Metabolic research | Metabolic research |
| Mechanism context | Semaglutide mimics GLP-1, enhancing glucose-dependent insulin secretion, reducing glucagon, slowing gastric emptying and reducing appetite through central mechanisms. | Tirzepatide is a novel dual agonist that simultaneously activates the GLP-1 and GIP receptors. This dual mechanism enhances glucose-dependent insulin secretion while suppressing glucagon release, slowing gastric emptying and promoting satiety through central appetite regulation. The additional GIP activity synergistically enhances metabolic effects beyond GLP-1 alone, contributing to the superior weight reduction observed in clinical trials. A half-life of ~5 days allows convenient weekly administration. |
| Evidence level | Not specified in profile | Not specified in profile |
Combined references
- NEJM — STEP 1 — Semaglutide 2.4mg for obesity
View source - NEJM — SELECT — Semaglutide cardiovascular benefits
View source - StatPearls (NCBI Bookshelf) — Pharmacology, dosing and clinical use of Tirzepatide
View source - Frontiers in Endocrinology (2022) — GIP/GLP-1 agonist tirzepatide for type 2 diabetes and obesity
View source - The Lancet (2018) — Clinical data and safety of tirzepatide in type 2 diabetes (Phase 2)
View source - New England Journal of Medicine (2022) — Tirzepatide once weekly in a clinical obesity study
View source - FDA Prescribing Information — Mounjaro (tirzepatide) prescribing information
View source - Mayo Clinic — Tirzepatide — clinical overview and patient information
View source